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Abstract Introduction
Factor X (FX) is a vitamin K-dependent plasma protein re-
quired for the intrinsic and extrinsic pathways ofblood coagula-
tion. F~s.. Di,.w is a hereditary FX deficiency which is char-
acterized clinically by a severe bleeding diathesis. The propo-
sita has a FX activity of < 1% and a FX antigen of < 5%. We
have determined the molecular basis of the defect in the FXst.
D.h,,gene by amplification of all eight exons with polymerase
chain reaction and subsequent sequence analysis. The patient is
homozygous for a G -* A transition in exon I at codon -20
(numbering the alanine at the NH2 terminus of the mature pro-
tein as +1), resulting in the substitution of arginine for glycine
in the carboxy-terminal part of the signal peptide. This amino
acid change occurs near the presumed cleavage site of the sig-
nal peptidase. We hypothesized that the mutation might pre-
vent cleavage by the signal peptidase which in turn would im-
pair proper secretion of the FX protein. To test this hypothesis,
we compared the expression of wild type and mutant FX cDNA
in a human kidney cell line. Wild type and mutant constructs in
the expression vector pCMV4 were introduced into the human
embryonic kidney cell line 293 by calcium phosphate transfec-
tion. FX antigen levels in the supernatant of the cells harboring
the wild type construct were 2.4 ig/10' cells per 24 h, whereas
antigen levels in media from cells containing the FXAsDT
construct were undetectable. No FX antigen was detected in the
cell lysates of cells transfected with the mutant construct. To
insure that the difference in protein levels was not due to a
difference in steady state levels of mRNA, Northern analysis
was performed on RNA from the cell lysates of both constructs.
The results showed a transcript of the same size, present in
roughly equal amounts, in both cases. Thus, the defect in the
signal sequence of DaubD exerts its effect posttranscrip-
tionally. F7soDo_ is the first described example of a bleed-
ing diathesis due to a mutation in the signal sequence. (J. Clin.
Invest. 1991. 88:1685-1689.) Key words: factor X * signal se-
quence * bleeding diathesis * factor X deficiency
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Factor X (FX)' is a vitamin K-dependent plasma glycoprotein
required for blood coagulation (1). It is synthesized in hepato-
cytes as a single polypeptide chain, or prepro-FX, and under-
goes several modifications before it is constitutively secreted
into plasma. In a cotranslational event, the signal sequence is
cleaved off from the NH2-terminal portion of the primary
translational product ofFX. Further posttranslational steps in-
clude y-carboxylation of 11 glutamic acid residues located near
the NH2 terminus, cleavage of the propeptide, glycosylation,
and beta hydroxylation. The amino acid sequence of FX has
been derived from FX cDNA's and direct amino acid analysis
(2-5). The gene has also been isolated and partially character-
ized. It has been mapped to chromosome 1 3q32-qter (6), where
it spans 25 kb; it consists of seven introns and eight exons
and has structural homology with the genes encoding the other
vitamin K-dependent clotting factors (7). The functional do-
mains of the protein are represented by different exons: exon I
codes for the signal sequence, exon H for the propeptide, and
the y-carboxyglutamic acid-rich domain, exon III for the short
aromatic acid-rich stack, exons IV and V for the epidermal
growth factor-like domains, exon VI for the activation peptide,
and exons VII and VIII for the catalytic domain (7).
Congenital FX deficiency is inherited as an autosomal re-
cessive trait (8). Considerable phenotypic heterogeneity exists
among FX variants (9-1 1). The molecular basis of congenital
FX deficiency has been completely elucidated in only three
families so far. Two of these are homozygous for defects in
exon 11 (12) and exon VIII (13), respectively. One compound
heterozygote has been reported (14). Here we report another
homozygous FX deficiency (FXs.,. Donnab) in which a point
mutation in exon I leads to a severe bleeding disorder in the
affected proposita.
Methods
Patient data. The proposita is a 16-yr-old female from Santo Domingo,
Dominican Republic, who came to medical attention because ofheavy
menstrual bleeding at menarche. This was associated with significant
blood loss, requiring transfusion, and on occasion, treatment with
prothrombin complex concentrates. Blood samples were obtained
from the proposita and her parents after informed consent. Prothrom-
bin time (PT) and activated partial thromboplastin time (aPTT) were
performed using standard methods. FX antigen levels were determined
by immunoassay using a FX-specific sandwich ELISA. Four different
monoclonal antibodies were used as capture antibodies (gift of Dr.
William Church, University ofVermont, and Dr. D. M. Monroe, Uni-
versity ofNorth Carolina). One ofthese has been extensively character-
ized and recognizes an epitope in the heavy chain (15); the other three
also recognize epitopes in the heavy chain. Plates are coated first with
1. Abbreviations used in this paper: aPTT, activated partial thrombo-
plastin time; FX, Factor X; PT, prothrombin; TBE, Tris-borate-EDTA
buffer.
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the monoclonal antibody; the second antibody is a rabbit polyclonal
anti-human FX (12). Factor X activity levels were determined using a
one-stage clotting assay.
DNA analysis. Genomic DNA was prepared from the patients' pe-
ripheral blood using standard methods (16), and Southern blots were
performed to determine whether the gene was grossly intact. 10 jig of
genomic DNA from the proposita and the same amount from a nonre-
lated normal control were digested with 30U ofEco RI at 370C for 3 h.
The digest was electrophoresed on a 0.8% agarose gel and transferred to
a nitrocellulose membrane according to the method of Southern (17).
A full-length human FX cDNA (gift of Dr. D. Stafford) was radiola-
belled with 32P dCTP by random priming using the manufacturer's
conditions (Boehringer-Mannheim Biochemicals, Indianapolis, IN).
20 ng of labelled probe with a sp act of 1.8 X 109 cpm/jig was added to
the filter incubating in 6X SSC, 0.01 M EDTA, 0.1 M K2H2P04, SX
Denhardt's solution, 0.5% SDS, and 250 jug/mi salmon sperm DNA.
After incubation for 12 h at 680C the filter was washed in 2x SSC, 0.5%
SDS twice for 15 min at room temperature, in 0. X SSC, 0.5% SDS for
45 min at 680C, and exposed to x-ray film at -70'C for 24 h.
All eight exons ofFX were isolated using the enzymatic amplifica-
tion technique (18). Synthetic oligonucleotides derived from intron
sequences flanking the 5' and 3' ends of each exon were used to prime
amplification (12). Hind III restriction sites were built in at the 5' ends
of each oligonucleotide. Target sequences were amplified in a 100-jil
volume containing 1 jig ofgenomic DNA, 10mM Tris-HCl pH 8.3, 50
mM KCl, 2.5 mM MgC12, 0.01% (wt/vol) gelatin, 0.2 jiM of each de-
oxyribonucleotide (dNTP:dCTP, dGTP, dATP, dTTP), 1 jiM of each
primer, and 1 U Taq polymerase. The samples were overlaid with 100
jIl mineral oil to prevent evaporation and subjected to 30 cycles of
denaturation at 94°C for 2 min, annealing at 55°C for 2 min, and
primer extension at 72°C for 3 min on a DNA Thermal Cycler R
(Perkin-Elmer Cetus, Emeryville, CA). The amplified DNA was elec-
trophoresed on a 2% agarose gel in Tris-borate-EDTA buffer (TBE) and
the amplified region cut out from the gel. The recovered gel slice was
crushed and incubated with 50 jl TBE, 50 jl phenol, and 50 ji chloro-
form:isoamyl alcohol (24:1) for 15 min at -70°C. After spinning for 15
min in a microfuge the supernatant was recovered and theDNA precip-
itated with ethanol. After digestion with Hind III the fragments were
subcloned into M13 sequencing vectors and sequenced as previously
described (19).
Exon I was also amplified as described above to perform restriction
analysis with Dde I. 30 base synthetic oligonucleotides derived from
the 5' untranslated region and from intron A were used in this amplifi-
cation to yield a DNA fragment of 213 bp containing exon I and a
single naturally occurring Dde I site. DNA fragments were electropho-
resed and purified as described above. Digestions were carried out ac-
cording to the manufacturer's conditions with Dde I (New England
Biolabs, Beverly, MA). Digested DNA was electrophoresed on a 6%
agarose gel (Nu Sieve GTG; FMC Corp., FMC BioProducts, Rockland,
ME) in TBE buffer. Exon I amplified from normal DNA was used as a
control in all restriction digests.
In vitro expression. A partial human FX cDNA which contains the
complete FX coding sequence, a translation initiation sequence, and
part of the 3' untranslated region was inserted in the multiple cloning
site of the phagemid pMA254. The point mutation found in exon I of
the FXst. Dowl gene was introduced into the pMA254-FX plasmid
by oligonucleotide hybridization (20) and the gapped duplex method.
The presence of the point mutation in the mutagenized plasmid was
confirmed by DNA sequence analysis. The plasmid pCMV4 was used
as the expression vector (21). The normal FXcDNA was inserted in the
multiple cloning site of this plasmid in order to express the wild type
FX. The expression plasmid of FXs.5 Dojn was constructed by dele-
tion of a Sma I-Sac II DNA fragment from the normal FXcDNA in
pCMV4. This fragment includes the nucleotide that is mutated in
FXs.. Dgw,. The deleted fragment was replaced by the correspond-
ing fragment ofpMA254 that carries the point mutation ofthe FXs.
Domh genotype. The correct insertion ofthe fragment and the presence
of the mutation were again confirmed by sequence analysis.
The constructs were introduced into the human embryonic kidney
cell line 293 by calcium phosphate transfection (22). All transfections
were done in duplicate. A mock transfection (no DNA) served as a
control. Cells were grown in DMEM/F12 medium in the presence of
10% FCS. 24 h before collecting samples, culture medium was changed
and fetal calf serum was omitted to eliminate any possibility of anti-
body cross-reactivity with bovine FX. The supernatant was collected
72 h after transfection and analyzed for the presence of FX antigen,
using the immunoassay described above. The transfected cells were
also collected, lysed, and assayed for the presence of FX. For the cell
lysis procedure, confluent cells in a 10-cm dish were washed twice with
PBS, then covered with buffer containing 0.5% NP-40, 60 mM
Na2HPO4, 40mM NaH2PO4, 10mM KCI, 1 mM MgSO4, and 50mM
2-mercaptoethanol. The cells were scraped from the plate and centri-
fuged at 12,000 g for 15 min at 40C. FX antigen levels in the superna-
tant were determined. Total RNA was isolated from the transfected
cells by the guanidinum-phenol-chloroform method (23). 10 jig oftotal
RNA was loaded on a formaldehyde-agarose (1%) gel and electropho-
resed for 2 h at 75 V. RNA was transferred onto a nitrocellulose filter,
probed with a radiolabelled FX cDNA, and exposed to x-ray film at
-70'C for 12 h.
Results
Clinical data andgene analysis. Results of coagulation studies
are described in Table I. The proposita has a markedly pro-
longed PT and aPTT. Factor assays revealed a FX activity of
< 1%; the activities ofall other coagulation factors were within
normal limits. The parents both had FX activity levels in an
intermediate range, 29-38%. The FX antigen levels were 5% of
normal in the proposita and 50% of normal in the parents
(Table I). Southern blot analysis of the proposita's EcoRI di-
gested DNA probed with an FX cDNA showed the same pat-
tern ofbands as normal DNA (data not shown). Thus, there is
no evidence of a gross gene deletion, insertion or rearrange-
ment.
Sequence analysis ofthe coding region and the exon-intron
junctions ofthe proposita's FX gene revealed a single base mis-
match when compared with the normal sequence. A G -- A
point mutation at the first nucleotide of codon -20 results in
the substitution ofan arginine (AGG) for a glycine (GGG) (Fig.
1). The mutation creates a new Dde I restriction site within
exon I (Fig. 1). Enzymatically amplified exon I from a mutant
allele therefore shows one additional Dde I site which can be
used for discrimination between a normal, a homozygous, and
a heterozygous genotype with respect to the mutation in exon I.
Dde I restriction of DNA amplified from exon I of a normal
control showed DNA fragments of 113 bp and 100 bp due to
the naturally occurring Dde I site (Fig. 2). In the DNA ampli-
fied from exon I of the proposita, the 100-bp fragment was
further cleaved into fragments of 70 bp and 30 bp due to the
Table L FactorX Coagulation Valuesfor Normal Control
and Santo Domingo Kindred
PT aPYI Antigen Activity
S S
Normal 9-12.5 22-35 10jg/ml 60-150%
Father 11.7 28.7 5 jig/mI 38%
Mother 12.4 32.6 5 jug/ml 29%
Patient 29.8 74.6 0.5 jg/ml <1%









Figure 1. Sequence analysis of exon I of FXsk mh. The
transition at the first nucleotide ofcodon -20 changes glycine
ginine. The recognition site for the restriction enzyme Dde I 4
where N is any nucleotide, is indicated by the bar. It is prest
FXSD but not in wild type.
additional Dde I site created by the mutation. She is tl
homozygous for the defect in exon I. Exon I amplified f
parents showed bands at 113 bp, 100 bp, 70 bp, and
indicating a heterozygous genotype.
In vitro expression system. To test the effect of th
mutation on FX expression we expressed a normal FL


















Figure 2. (A) Restriction digests of amplified exon I from the
*._ I -. _t __ -_-__ !_ _ ses_sita and her parents. Dde I restriction digest ofamplified exon I from
a normal control, yielding fragments of 113 and 100 bp, is shown on
the left. In the center lane, the digest from the proposita shows an
absence of the 100-bp band, and its replacement by the predicted 70-
and 30-bp fragments. Similar analysis on the father ofthe proposita
discloses heterozygosity, with the 100 bp, and the 70- and 30-bp frag-
ments, all present. Analysis of the mother yielded the same results
(not shown). (B) Restriction map of amplified exon I. Priming oligo-
mers (ref. 12) are marked by the crosshatched boxes. The single nat-
urally occurring Dde I site divides the exon into 113- and I00-bp
fragments. The Santo Domingo mutation creates an additional Dde I

















transient expression system (Table II). The wild type FX con-
struct yielded a FX antigen concentration in the cell superna-
tant of 300 ng/ml per 24 h. Normalized to the number of cells,
this concentration represents 2.4 ,ugFX antigen/107 cells per 24
h. In contrast, no FX antigen was detectable in the supernatant
of the cells that were transfected with the FXsnto Domino con-
struct. The lower limit of detection of the ELISA is 10 ng/ml.
When the transfected cells were lysed and assayed for the pres-
ence of FX, no FX protein was detectable in the cells trans-
fected with the Santo Domingo construct. FX was present in
the cells transfected with the wild type construct at a concentra-
tion of 300 ng/ml. Northern blot analysis of cell lysates showed
a FX mRNA of the same size, present in roughly equal
amounts, in both the wild type and the Santo Domingo trans-
fectants (Fig. 3).
Discussion
herefore Analysis ofthe gene coding for FXs.,t Doning disclosed that the
irom the FX deficiency in this patient is associated with a single point
1 30 bp, mutation in exon I, which encodes the signal sequence. The
proposita is homozygous for the defect, and is severely affected,
ie point with a FX activity of < 1% and FX antigen of only 5%. Her
ccDNA parents are heterozygous for the defect and thus, in accordance
ion in a with the autosomal recessive character of FX deficiency,Lion in asymptomatic. FXsao mmiv is the fourth FX deficiency that
has been completely elucidated at the molecular level ( 12-14).
It is the first mutation in a FX deficiency, however, in which
the causative effect ofthe mutation has been proved by expres-
sion in vitro of the mutant cDNA and subsequent analysis of
the expressed phenotype. The results ofour expression experi-
ments in vitro parallel the situation in vivo, as the lack ofFX
expression in vitro correlates well with the low FX antigen
levels in the plasma of the proposita. We therefore conclude
that the point mutation in exon I and the resulting substitution
of arginine for glycine at position -20 (numbering the alanine
at the NH2 terminus of the mature protein as +1) cause the
FXsantO Domingo phenotype.
Amino acid -20 is part of the prepro region of the FX
protein. The signal sequence serves the function of targeting
the elongating polypeptide chain to the site of translocation
into the endoplasmic reticulum, where a number of critical
posttranslational steps occur. The signal sequence is cleaved
from the protein in a cotranslational event (24) as the newly
synthesized protein is translocated into the lumen ofthe endo-
plasmic reticulum. The propeptide, which is still attached and
serves as a recognition site for the 'y-carboxylase (25), is cleaved
_____ in a subsequent posttranslational modification. While the NH2
terminus ofthe mature protein unambiguously indicates where
'PIropo- the propeptide is cleaved, the cleavage site of the signal se-
Table II. FactorX ELISA Results in Transfectants
Supernatant Cell lysate
Mock ND ND
FX,,,t 2.4 gg/l07cells per 24 h 300 ng/ml
FXSD ND ND
ND, not detectable. All transfections done in duplicate.
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Figure 3. Northern analysis of total
--1.51 kb RNA from transfected cells. 10 usg to-
tal RNA from mock transfected (lane
1), wild type (lane 2), and FXSD-
transfected cells (lane 3) were loaded
on a gel and transferred to nitrocellu-
lose. The blot was hybridized against
radiolabelled human FX cDNA. The
1.5 1-kb FX transcript is present in the
wild type and FXSD transfectants.
quence in the human prepro FX has not been established with
certainty.
Several lines of evidence suggest that the signal peptidase
cleavage site is located between Ser(- 18) and Leu(- 17). First,
organization of the FX gene follows a structure-function pat-
tern whereby the coding regions for the various functional do-
mains ofthe FX protein are found in different exons (7). Exon I
encodes the signal peptide domain ofall vitamin K-dependent
coagulation factors. Exon I in the FX gene codes for amino
acids Met(-40) through Leu(- 18). Thus, exon I exactly en-
codes the complete signal sequence assuming the signal pepti-
dase cleavage site is COOH-terminal to Leu(- 18). Second, the
COOH termini of signal sequences are characterized by small,
neutral amino acid residues at positions -1 and -3 (number-
ing the very COOH-terminal amino acid of the signal sequence
as -1) (26). The conservation of small neutral amino acids at
these residues is sometimes referred to as the -1, -3 rule. In
aligning various signal sequences, von Heijne was able to empir-
ically develop rules that allow prediction ofthe actual cleavage
site ofthe signal sequence by signal peptidase (26). Application
ofthese rules to FX predicts a highly favorable cleavage site for
the signal peptidase between residues -18 and -17 (Fig. 4).
Finally, presumption of cleavage at this point is further sup-
ported by the fact that the bovine FX signal sequence, which is
-40 -35 -30
Met Gly Arg Pro Leu His Leu Val Leu Leu Ser Ala Ser Leu




-25 -20 -18 -17 -1 +1
Ala Gly Leu Leu Leu Leu Gly Glu Seri Leu Arg Ala
GCT GGC CTC CTGCTGCTC GGG GAA AGTC TG
EXONI'f EXON 1I4
Figure 4. The prepropeptide of human Factor X. The first 40 residues
of the translation product are absent from the mature protein that
circulates in plasma. These residues are generally numbered -1 to
-40, proceeding back from the start site of the mature protein. The
cleavage site for the prepeptide is most likely at - 17/-18, so that
-18 corresponds to residue -1 in signal peptide nomenclature. Simi-
larly, the site of substitution in FXSDis -3.
very similar to the human FX signal sequence, has been re-
ported to be cleaved exactly at this point (27).
The substitution of Arg for Gly, occurring at residue -20
numbering from the NH2 terminus ofthe mature protein, falls
at the critical -3 residue, numbering from the presumed
COOH terminus of the signal sequence. Consistent with the
-1, -3 rule, amino acid -3 is a small neutral residue in the
majority ofprokaryotic and eukaryotic signal sequences. Based
on data generated in prokaryotic systems, the Gly Arg muta-
tion at -3 is predicted to impair processing profoundly. An Ala
Arg mutation at -3 ofthe maltose bindingprotein in Esche-
richia coli results in extremely inefficient processing, with only
7% of premaltose binding protein being cleaved to mature
product (28). More conservative substitutions, e.g., glycine, va-
line, leucine, had no effect on processing. One possibility then
is that the substitution introduced in FXsD by Arg-3 may inter-
fere with processing (cleavage by signal peptidase) in a similar
manner.
There are few data regarding naturally occurring substitu-
tions in human signal sequences, and the substitutions previ-
ously reported do not occur at the carboxy terminus of the
signal peptide. Albumin Redhill (29) is characterized by an Arg
-- Cys substitution within the propeptide, which appears to
create an alternate cleavage site for signal peptidase. The result-
ing albumin variant contains a single extra NH2-terminal
amino acid but is not associated with any disease state. Simi-
larly, a 9-bp insertion/deletion within the hydrophobic core of
the signal peptide of human apolipoprotein B has been re-
ported, but this appears to be a benign polymorphism with no
influence on signal peptide function (30). Arnold et al. have
recently reported a mutation within the signal sequence of the
preproparathyroid hormone gene, in association with a case of
familial isolated hypoparathyroidism (31). The mutation (Cys
-- Arg) occurs within the hydrophobic core of the signal se-
quence. Interpretation of the data in this case is not entirely
straightforward, since the patient and an affected sibling are
heterozygous for the signal peptide mutation and severely af-
fected, while the father of these two patients, also heterozygous,
is not clinically affected. In contrast, the case of FXSD is less
ambiguous, since the parents are both heterozygous for the
mutation, have intermediate FX activity levels, and are clini-
cally unaffected, whereas the proband, homozygous for the
mutation, has a FX activity level of < 1%, and is severely af-
fected clinically.
To determine whether the signal peptide mutation gives
rise to the observed phenotype, constructs bearing wild type
Factor X and FXSD were transfected into a human embryonic
kidney cell line. Such a eukaryotic expression system allows
one to determine the functional consequences of the mutation
on cellular secretion. While the wild type was normally ex-
pressed as expected, no detectable FX antigen was present in
the media of the cells harboring the FXSD construct. The nature
of the antibodies used in the ELISAs, one polyclonal, the other
a monoclonal directed against an epitope in the catalytic do-
main, makes it unlikely that an aberrantly processed FX, with
an additional NH2-terminal sequence, was present but not rec-
ognized. Differences in expression of the two constructs at the
level of transcription were ruled out by Northern analysis,
which demonstrates equivalent steady-state levels of FX
mRNA (Fig. 3). Analysis of cell lysates from the transfected
cells showed that FX antigen was present in cells transfected
with the wild type construct, but absent in those harboring the
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FXSD construct. The precise mechanism of the profound im-
pairment of expression is unclear. Future studies using in vitro
systems will be directed toward determining which of several
possible mechanisms, including failure oftranslation, oftarget-
ing, or of signal sequence cleavage, accounts for the impaired
expression.
In summary, we have determined the causative mutation in
a case of severe Factor X deficiency. The proposita is homozy-
gous for aG -- A transition that results in a glycine -* arginine
substitution within the signal peptide. Restriction analysis dem-
onstrates that the parents are heterozygous for the same muta-
tion; their FX activity levels are 30-40% range, and the pro-
posita's is < 1%. Expression of the mutation in a mammalian
expression system demonstrates that, in contrast to wild type
FX, Factor XsD is not secreted into the media or detectable in
the cell lysates. Thus, the signal sequence mutation accounts
for the observed phenotype. Among the three previously de-
scribed mutations causing Factor X deficiency, and among
> 200 mutations causing F.IX deficiency, there have been no
examples of signal peptide mutations causing a bleeding diath-
esis (12-14, 32). Further study ofthis mutation may yield addi-
tional insights into the mechanism of action of signal se-
quences.
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